Bio-Rad Launches SEQuoia Express Stranded RNA Library Prep Kit
Bio-Rad’s SEQuoia Express Stranded RNA Library Prep Kit is designed to construct efficient RNA sequencing workflows.
Bio-Rad announced the launch of the SEQuoia Express Stranded RNA Library Prep Kit on June 6, 2022. The kit is designed to construct robust libraries for efficient RNA sequencing (RNA-Seq) workflows in comprehensive transcriptome profiling.
According to a company press release, the SEQuoia is a three-tube kit that uses a novel reverse transcriptase and a ligation-free adaptor addition chemistry to produce a reproducible, quantitative RNA-Seq library in three hours. The kit allows researchers to construct robust libraries that capture messenger RNA and long noncoding RNA (> 200 binding proteins) transcripts for differential gene expression analysis and novel transcript delivery.
“Current RNA library preparation approaches are time-consuming, complex, and potentially error-prone, with sample loss observed at each stage in processes with multiple steps,” said Simon May, executive vice-president and president, Life Science Group, Bio-Rad, in the press release. “Bio-Rad offers scientists an enhanced solution, combining its rapid NGS [next generation sequencing] library preparation with integrated data analysis to overcome these difficulties and enable the widespread adoption of RNA-based sequencing."
Source: Bio-Rad
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
In Wake of Trump Tariffs, Lilly Plans New US Pharmaceutical Manufacturing Sites
February 26th 2025Previous domestic capital expansion commitments since 2020 had been made in Research Triangle Park and Concord, both in North Carolina; Kenosha County, Wisconsin; Lebanon, Indiana; and Lilly’s home city of Indianapolis.
Cosette Pharmaceuticals Adds to Dermatology and Women’s Health Portfolio with Mayne Pharma Purchase
Published: February 26th 2025 | Updated: February 26th 2025While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.
